Assessing PD-L1 status in mRCC treated with first-line immune-based combinations: a meta-analysis.
Sign Up to like & getrecommendations! Published in 2022 at "Immunotherapy"
DOI: 10.2217/imt-2021-0261
Abstract: Aims: We performed a meta-analysis to investigate the predictive value of PD-L1 in metastatic renal cell carcinoma (mRCC) patients receiving immune-based combinations versus sunitinib monotherapy. Materials & Methods: Outcomes of interest included OS and PFS;… read more here.
Keywords: meta analysis; mrcc; assessing status; based combinations ... See more keywords